<?xml version="1.0" encoding="utf-8"?> <feed xmlns:dc="http://dublincore.org/documents/dcmi-namespace/" xmlns:media="http://search.yahoo.com/mrss/" xmlns="http://www.w3.org/2005/Atom"> <title type="text">Vaxil Bio Ltd.</title> <subtitle type="text">Contains the last 20 releases</subtitle> <id>uuid:ccb099ac-a38a-4a7b-be95-5e4e6b96d409;id=11196</id> <rights type="text">Copyright 2024, Vaxil Bio Ltd.</rights> <updated>2024-08-21T12:09:12Z</updated> <author> <name>newsdesk@globenewswire.com (NewsDesk)</name> <uri>http://www.globenewswire.com/LegacyRss?Length=4</uri> <email>newsdesk@globenewswire.com</email> </author> <link rel="alternate" href="https://www.globenewswire.com/atomfeed/organization/xg-uLJLg0vJnYRIeR2Qx6g==" /> <link rel="self" href="https://www.globenewswire.com/atomfeed/organization/xg-uLJLg0vJnYRIeR2Qx6g==" /> <entry> <id>https://www.globenewswire.com/news-release/2024/08/21/2933473/0/en/Vaxil-Bio-Enters-Into-Definitive-Agreement-With-Green-Data-Centers-for-Reverse-Take-Over.html</id> <title type="text">Vaxil Bio Enters Into Definitive Agreement With Green Data Centers for Reverse Take Over</title> <published>2024-08-21T12:09:12Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/08/21/2933473/0/en/Vaxil-Bio-Enters-Into-Definitive-Agreement-With-Green-Data-Centers-for-Reverse-Take-Over.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify"><strong><em>Not for distribution to United States newswire services or for release, publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities Laws.</em></strong></p>]]></content> <dc:identifier>2933473</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Wed, 21 Aug 2024 12:09 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/05/27/2888434/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Green-Data-in-Respect-of-A-Proposed-Reverse-Takeover.html</id> <title type="text">Vaxil Bio Enters Into Letter of Intent With Green Data in Respect of A Proposed Reverse Takeover</title> <published>2024-05-27T10:30:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/05/27/2888434/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Green-Data-in-Respect-of-A-Proposed-Reverse-Takeover.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left"><strong><em>Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States</em></strong><br></p>]]></content> <dc:identifier>2888434</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Mon, 27 May 2024 10:30 GMT</dc:modified> <dc:subject>Changes in company's own shares</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> <dc:subject>Mergers and Acquisitions</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/03/04/2839727/0/en/Vaxil-Bio-Proposed-Reverse-Takeover-with-Copper-Bullet-Terminated-and-Update-of-Research-Activities.html</id> <title type="text">Vaxil Bio Proposed Reverse Takeover with Copper Bullet Terminated and Update of Research Activities</title> <published>2024-03-04T14:57:41Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/03/04/2839727/0/en/Vaxil-Bio-Proposed-Reverse-Takeover-with-Copper-Bullet-Terminated-and-Update-of-Research-Activities.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify"><strong><em>Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States</em></strong></p>]]></content> <dc:identifier>2839727</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Mon, 04 Mar 2024 14:58 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> <dc:subject>Major shareholder announcements</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2024/01/10/2807452/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Copper-Bullet-Mines-in-Respect-of-a-Proposed-Reverse-Takeover.html</id> <title type="text">Vaxil Bio Enters Into Letter of Intent With Copper Bullet Mines in Respect of a Proposed Reverse Takeover</title> <published>2024-01-10T20:01:46Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2024/01/10/2807452/0/en/Vaxil-Bio-Enters-Into-Letter-of-Intent-With-Copper-Bullet-Mines-in-Respect-of-a-Proposed-Reverse-Takeover.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify"><strong><em>Not for distribution to United States newswire services or for release publication, distribution or dissemination directly, or indirectly, in whole or in part, in or into the United States</em></strong></p>]]></content> <dc:identifier>2807452</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Wed, 10 Jan 2024 20:02 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> <dc:subject>Corporate Action</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/08/02/2717467/0/en/Vaxil-Provides-Update-on-Research-Activities-and-Management-Changes.html</id> <title type="text">Vaxil Provides Update on Research Activities and Management Changes</title> <published>2023-08-02T21:00:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/08/02/2717467/0/en/Vaxil-Provides-Update-on-Research-Activities-and-Management-Changes.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="justify">NESS-ZIONA, Israel, Aug. 02, 2023 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. ("<strong>Vaxil</strong>" or the "<strong>Company</strong>") (TSX VENTURE:VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases announces the follow update on its research activities and changes in senior management.<br></p>]]></content> <dc:identifier>2717467</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Wed, 02 Aug 2023 21:00 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> <dc:subject>Changes in company's own shares</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2023/04/24/2653458/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html</id> <title type="text">Vaxil’s Annual and Special Shareholders Meeting</title> <published>2023-04-24T23:50:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2023/04/24/2653458/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2653458</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Mon, 24 Apr 2023 23:50 GMT</dc:modified> <dc:subject>Annual Meetings & Shareholder Rights</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/03/07/2397873/0/en/Vaxil-Provides-Update-on-Research-Activities.html</id> <title type="text">Vaxil Provides Update on Research Activities </title> <published>2022-03-07T12:50:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/03/07/2397873/0/en/Vaxil-Provides-Update-on-Research-Activities.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="left">Not for distribution by US newswire or in United States</p>]]></content> <dc:identifier>2397873</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Mon, 07 Mar 2022 12:50 GMT</dc:modified> <dc:subject>Research Analysis and Reports</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/02/08/2381423/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html</id> <title type="text">Vaxil’s Annual and Special Shareholders Meeting</title> <published>2022-02-08T22:30:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/02/08/2381423/0/en/Vaxil-s-Annual-and-Special-Shareholders-Meeting.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2381423</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Tue, 08 Feb 2022 22:30 GMT</dc:modified> <dc:subject>Annual Meetings & Shareholder Rights</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2022/01/04/2360965/0/en/Vaxil-Provides-Final-Results-on-Its-Previously-Disclosed-Research-With-Ben-Gurion-University-of-the-Negev.html</id> <title type="text">Vaxil Provides Final Results on Its Previously Disclosed Research With Ben-Gurion University of the Negev</title> <published>2022-01-04T15:02:26Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2022/01/04/2360965/0/en/Vaxil-Provides-Final-Results-on-Its-Previously-Disclosed-Research-With-Ben-Gurion-University-of-the-Negev.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2360965</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Tue, 04 Jan 2022 15:02 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/12/13/2351189/0/en/Vaxil-Announces-Resignation-of-Director.html</id> <title type="text">Vaxil Announces Resignation of Director</title> <published>2021-12-13T21:30:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/12/13/2351189/0/en/Vaxil-Announces-Resignation-of-Director.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Not for distribution by US newswire or in United States <pre>Not for distribution by US newswire or in United States</pre>]]></content> <dc:identifier>2351189</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Mon, 13 Dec 2021 21:30 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/11/12/2333670/0/en/Vaxil-Announces-Change-of-Auditor.html</id> <title type="text">Vaxil Announces Change of Auditor</title> <published>2021-11-12T22:10:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/11/12/2333670/0/en/Vaxil-Announces-Change-of-Auditor.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States</p>]]></content> <dc:identifier>2333670</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Fri, 12 Nov 2021 22:10 GMT</dc:modified> <dc:subject>Press releases</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/11/11/2332560/0/en/Vaxil-Provides-Update-on-Acquisition-of-Short-Wave-Pharma-Inc.html</id> <title type="text">Vaxil Provides Update on Acquisition of Short Wave Pharma Inc.</title> <published>2021-11-11T12:55:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/11/11/2332560/0/en/Vaxil-Provides-Update-on-Acquisition-of-Short-Wave-Pharma-Inc.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Not for distribution by US newswire or in United States <pre>Not for distribution by US newswire or in United States</pre>]]></content> <dc:identifier>2332560</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Thu, 11 Nov 2021 12:55 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Mergers and Acquisitions</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/10/14/2314478/0/en/Vaxil-Signs-Letter-of-Intent-to-Acquire-a-100-Interest-in-Short-Wave-Pharma-Inc.html</id> <title type="text">Vaxil Signs Letter of Intent to Acquire a 100% Interest in Short Wave Pharma Inc.</title> <published>2021-10-14T14:52:29Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/10/14/2314478/0/en/Vaxil-Signs-Letter-of-Intent-to-Acquire-a-100-Interest-in-Short-Wave-Pharma-Inc.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2314478</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Thu, 14 Oct 2021 14:53 GMT</dc:modified> <dc:subject>Mergers and Acquisitions</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/10/12/2312710/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html</id> <title type="text">Vaxil Announces Progress on Research and Development Activities </title> <published>2021-10-12T13:07:40Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/10/12/2312710/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2312710</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Tue, 12 Oct 2021 13:08 GMT</dc:modified> <media:content medium="image" type="image/jpeg" width="600" url="https://ml.globenewswire.com/Resource/Download/6d473cdd-5542-4a4e-a776-f30bc192e974"> <media:text type="html"><![CDATA[<p> <a href="https://www.globenewswire.com/news-release/2021/10/12/2312710/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html"> <img src="https://ml.globenewswire.com/Resource/Download/6d473cdd-5542-4a4e-a776-f30bc192e974" width="600" align="left" border="0" alt="Figure 1" title="In vivo mice survival in experimental CRC liver metastasis model" /> </a> </p><br clear="all" />]]></media:text> <media:credit role="publishing company">GlobeNewswire Inc.</media:credit> </media:content> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/09/29/2305285/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html</id> <title type="text">Vaxil Announces Progress on Research and Development Activities</title> <published>2021-09-29T11:50:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/09/29/2305285/0/en/Vaxil-Announces-Progress-on-Research-and-Development-Activities.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2305285</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Wed, 29 Sep 2021 11:50 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/08/04/2274478/0/en/Vaxil-Announces-Changes-to-Senior-Management-and-Provides-Updates-on-Current-Research-and-Development-Work.html</id> <title type="text">Vaxil Announces Changes to Senior Management and Provides Updates on Current Research and Development Work</title> <published>2021-08-04T11:50:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/08/04/2274478/0/en/Vaxil-Announces-Changes-to-Senior-Management-and-Provides-Updates-on-Current-Research-and-Development-Work.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2274478</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Wed, 04 Aug 2021 11:50 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Directors and Officers</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/05/31/2238803/0/en/Vaxil-Provides-Research-and-Development-Update.html</id> <title type="text">Vaxil Provides Research and Development Update</title> <published>2021-05-31T11:50:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/05/31/2238803/0/en/Vaxil-Provides-Research-and-Development-Update.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2238803</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Mon, 31 May 2021 11:50 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/05/05/2223943/0/en/Vaxil-Announces-CEO-Resignation.html</id> <title type="text">Vaxil Announces CEO Resignation</title> <published>2021-05-05T21:00:00Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/05/05/2223943/0/en/Vaxil-Announces-CEO-Resignation.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2223943</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Wed, 05 May 2021 21:00 GMT</dc:modified> <dc:subject>Directors and Officers</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/03/11/2191688/0/en/Vaxil-Announces-2021-Reseach-and-Development-Strategy-and-Progress.html</id> <title type="text">Vaxil Announces 2021 Reseach and Development Strategy and Progress</title> <published>2021-03-11T20:51:13Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/03/11/2191688/0/en/Vaxil-Announces-2021-Reseach-and-Development-Strategy-and-Progress.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[Not for distribution by US newswire or in United States <pre>Not for distribution by US newswire or in United States</pre>]]></content> <dc:identifier>2191688</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Thu, 11 Mar 2021 20:51 GMT</dc:modified> <dc:subject>Company Announcement</dc:subject> <dc:subject>Health</dc:subject> </entry> <entry> <id>https://www.globenewswire.com/news-release/2021/02/17/2177422/0/en/Vaxil-Provides-Strategy-Update-From-Conclusion-of-COVID-19-Challenge-Study.html</id> <title type="text">Vaxil Provides Strategy Update From Conclusion of COVID-19 Challenge Study</title> <published>2021-02-17T18:25:19Z</published> <updated>2024-11-24T17:36:15Z</updated> <link rel="alternate" href="https://www.globenewswire.com/news-release/2021/02/17/2177422/0/en/Vaxil-Provides-Strategy-Update-From-Conclusion-of-COVID-19-Challenge-Study.html" /> <category term="TSX-V:VXL" scheme="https://www.globenewswire.com/rss/stock" /> <category term="CA92243L1076" scheme="https://www.globenewswire.com/rss/ISIN" /> <content type="html"><![CDATA[<p align="center">Not for distribution by US newswire or in United States<br></p>]]></content> <dc:identifier>2177422</dc:identifier> <dc:language>en</dc:language> <dc:publisher>GlobeNewswire Inc.</dc:publisher> <dc:contributor>Vaxil Bio Ltd.</dc:contributor> <dc:modified>Wed, 17 Feb 2021 18:25 GMT</dc:modified> <dc:subject>Health</dc:subject> <dc:subject>Product / Services Announcement</dc:subject> </entry> </feed>